U.S. SEC sues Mylan for concealing possible loss tied to EpiPen

(Reuters) – The U.S. Securities and Exchange Commission on Friday sued Mylan NV (O:), accusing it of failing to timely disclose a possible loss related to a Department of Justice probe into whether the company overcharged Medicaid by hundreds of millions of dollars for sales of the EpiPen Auto-Injector.

In a complaint filed with the federal court in Washington, D.C., the SEC accused Mylan of misclassifying EpiPen, which is used to treat severe allergic reactions, as a “generic” or “non-innovator” drug.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.